APP669-711

Val-Lys-Met-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
: (Trifluoroacetate Form)
: (M.W. 4688.3) C₂₁₀H₃₂₅N₅₇O₆₁S₂
: A Factor of Plasma Biomarker for Cerebral Amyloid

Package	Price(Yen)	Availability	Quantity
Vial 0.5 mg	30,000	Ships within 1-3 business days
バルク見積もり

Solubility: 0.1% NH₄OH or DMSO (1 mM)

N. Kaneko, R. Yamamoto, T. Sato, and K. Tanaka, Proc. Jpn. Acad. B, 90, 104 (2014). (Identification in plasma)
N. Kaneko, A. Nakamura, Y. Washimi, T. Kato, T. Sakurai, Y. Arahata, M. Bundo, A. Takeda, S. Niida, K. Ito, K. Toba, K. Tanaka, and K. Yanagisawa, Proc. Jpn. Acad. B, 90, 353 (2014). (Correlation between APP669-711/Aβ1-42 in plasma and cerebral amyloid deposition)
A. Nakamura, N. Kaneko, V.L. Villemagne, T. Kato, J. Doecke, V. Dore, C. Fowler, Q.X. Li, R. Martins, C. Rowe, T. Tomita, K. Matsuzaki, K. Ishii, K. Ishii, Y. Arahata, S. Iwamoto, K. Ito, K. Tanaka, C.L. Masters, and K. Yanagisawa, Nature(London), 554, 249 (2018). (APP669-711/Aβ1-42 in plasma as a biomarker for Alzheimer's disease)